Profile

Our laboratory is centered on deciphering how pathological mechanical forces and microenvironmental stress reprogram cellular signaling to drive aggressive and chronic diseases, including fatal cancers, cardiac hypertrophy presenting risk to heart failure, neurodegeneration, aging-related decline, and microbiome-immune dysfunction. We aim to delineate the molecular mechanisms of mechano-regulation, stress-induced inflammation, redox & metabolic plasticity, and cellular dormancy to enable predictive biomarker discovery and drug target identification.
We promote a clinically oriented vision in which mechanotransductive pathways serve as platforms for minimally invasive diagnostics, early risk stratification, prognostic monitoring, and pharmacological intervention. Our group integrates mechanobiology, mechanomics, multi-omics, epigenetic profiling, advanced disease models, and pharmacology to bridge fundamental disease biology with actionable therapeutic strategies. We identify circulating and tissue-based mechanosensitive biomarkers-such as stress-responsive oligomeric proteins and SUMOylation and glycosylation signatures-to predict disease progression, therapeutic response, and recurrence risk.
In cancers, particularly glioblastoma, we deconstruct stress-adaptive survival circuits and target recurrence-prone dormant populations through rational mechanotherapeutic interventions. In cardiac hypertrophy and neurodegenerative conditions, we focus on restoring mechanical and metabolic homeostasis using validated Rasayana-derived bioactives and nutraceutical regulators. Our integrated, multimodal framework has generated biomarker-guided mechanotherapies, promising intellectual property, and scalable, non-toxicity therapeutic leads. By advancing causal, mechanism-driven interventions beyond symptomatic or surgical management, our work aligns with precision medicine priorities and India's vision for affordable, innovation-led healthcare.